1. In Vivo
  2. >>Global Vision

Intuitive’s da Vinci: Will Familiarity Breed Success?

 
• By Ashley Yeo

Robotic soft-tissue MIS pioneer Intuitive Surgical continues to advance its offering in this disruptive area of medical technology. Having weathered an adverse incident-related storm, it is putting efforts into driving OUS business, broadening surgical applications, and convincing the doubters about robotic surgery’s place and role in the catalog of care delivery.

Quietly and steadily, it seems, Intuitive Surgical Inc., manufacturer of the da Vinci Surgical System for robotic-assisted surgery (RAS), is beginning to do two things very well: laying to rest the banner headlines and negative stories from 2012–13 relating to its teething problems, and convincing the traditionalists that minimally invasive RAS has a big place in the operating room of the future.

The OR of the present, in fact. The very first da Vinci surgery was performed in Frankfurt, Germany, in 2000. After a slow start, global usage and installation numbers have...

More from Global Vision

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By David Wild

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Unpacking The Impact Of Trump’s Tariffs On Drug Pricing And Production

 
• By Ed Silverman

Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.

Barcelona’s S2 Xpeed Accelerates Hardware-Based Medtech Start-Ups From Prototype To Market

 
• By Marion Webb

S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.

More from In Vivo